Switch theme
Sign up to access all valuation multiples
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
2016
50
LTM Revenue n/a
LTM EBITDA -$92.1M
$29.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cybin has a last 12-month revenue of n/a and a last 12-month EBITDA of -$92.1M.
In the most recent fiscal year, Cybin achieved revenue of n/a and an EBITDA of -$54.8M.
Cybin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cybin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$35.9M | -$54.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$47.3M | -$33.2M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cybin's stock price is CAD 9 (or $7).
Cybin has current market cap of CAD 196M (or $137M), and EV of CAD 42.2M (or $29.5M).
See Cybin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.5M | $137M | XXX | XXX | XXX | XXX | $-2.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cybin has market cap of $137M and EV of $29.5M.
Cybin's trades at n/a LTM EV/Revenue multiple, and -0.3x LTM EBITDA.
Analysts estimate Cybin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cybin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $29.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCybin's NTM/LTM revenue growth is Infinity%
Cybin's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Cybin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cybin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cybin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 53% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cybin acquired XXX companies to date.
Last acquisition by Cybin was XXXXXXXX, XXXXX XXXXX XXXXXX . Cybin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cybin founded? | Cybin was founded in 2016. |
| Where is Cybin headquartered? | Cybin is headquartered in Canada. |
| How many employees does Cybin have? | As of today, Cybin has 50 employees. |
| Who is the CEO of Cybin? | Cybin's CEO is Mr. Douglas Drysdale. |
| Is Cybin publicy listed? | Yes, Cybin is a public company listed on NEOE. |
| What is the stock symbol of Cybin? | Cybin trades under CYBN ticker. |
| When did Cybin go public? | Cybin went public in 2020. |
| Who are competitors of Cybin? | Similar companies to Cybin include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cybin? | Cybin's current market cap is $137M |
| What is the current EBITDA of Cybin? | Cybin's last 12-month EBITDA is -$92.1M. |
| What is the current EV/EBITDA multiple of Cybin? | Current EBITDA multiple of Cybin is -0.3x. |
| Is Cybin profitable? | Yes, Cybin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
